GPhA Tactics In Fight Against Calif. Biosimilar Bill Draw FDA Attention
This article was originally published in The Pink Sheet Daily
Executive Summary
The trade group stopped disseminating an advertisement opposing notification legislation because the agency said it could create confusion about FDA’s stance; GPhA continues to oppose the California measure, which faces an Oct. 13 deadline for the governor’s signature or veto.